Werewolf Therapeutics, Inc. (HOWL) Net earnings per share growth forecast for next year
Werewolf Therapeutics develops intelligent immunotherapy that activates drugs exclusively within tumors to protect healthy tissues. The consensus EPS growth rate for the coming year reflects market expectations, with the current value standing at 34.10. Werewolf Therapeutics is implementing the PREDATOR system for oncology centers to reduce treatment toxicity. Patent protection and stringent FDA requirements create significant barriers to entry for new players.
Metric breakdowns and analytics for Werewolf Therapeutics, Inc. (HOWL)
- price and consensus price forecast:
- market capitalization details:
- company book value details:
- company liabilities and liquidity data:
Debt to Equity Werewolf Therapeutics|HOWL - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio Werewolf Therapeutics Inc.|HOWL - Company Total Indebtedness|Debt to Book Value Werewolf Therapeutics|HOWL - Amount of Long-Term Liabilities|Company Short-Term Debts Werewolf Therapeutics|Quick Ratio werewolftx.com
- earnings and market ratios statistics:
HOWL - Company Net Income|Expected Profit Werewolf Therapeutics|HOWL - Company Value to Net Income|Forward P/E Multiple Werewolf Therapeutics Inc.|HOWL - PEG Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Werewolf Therapeutics|HOWL - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share for the last 12 months Werewolf Therapeutics|HOWL - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months werewolftx.com|HOWL - Net earnings per share growth this year|Earnings growth forecast for next year Werewolf Therapeutics
Analysis of all company metrics:Werewolf Therapeutics
For Werewolf Therapeutics (HOWL), whose success is driven by the biological efficacy of its drugs rather than macro cycles, this indicator reflects market consensus expectations for changes in net profit. When analyzing EPS prospects for the coming year, investors assess the percentage deviation of the projected earnings per share from its current value. The trend of this metric serves as an indicator of capital appetite for high-risk assets within the growth sector.
Direct competitors
Net earnings per share growth forecast for next year ImmunityBio Corp|Expected earnings per share growth for next year Immunocore Corp (IMCR)|Net earnings per share growth forecast for next year Janux Therapeutics (JANX)|Expected earnings per share growth for next year arcusbio.com RCUS|Zymeworks - Expected earnings per share growth for next year|Earnings growth forecast for next year Tango Therapeutics Inc TNGX|IOVA - Net earnings per share growth forecast for next year|IMTX (Immatics Biotechnologies) - Projected earnings per share growth rate for next year|Xencor, Inc. (XNCR) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year compasstherapeutics.com (CMPX)|Expected earnings per share growth for next year REPL|LYEL - Net earnings per one share growth forecast for next year|Expected earnings per share growth for next year IPHA (Innate Pharma, S.A.)|Projected earnings per share increase next year PYXS|Earnings growth forecast for next year CGEN (Compugen)|Expected earnings per share trend next year IOBT|Sutro Biopharma - Earnings growth forecast for next year|Expected net earnings per share growth next year MiNK Therapeutics Inc.|immixbio.com (IMMX) - Net earnings per share growth forecast for next year|ALX Oncology Holdings Inc. - Expected earnings per share trend next year|CUE (Cue Biopharma, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year PDS Biotechnology Corp|Net earnings per share growth forecast for next year Sonnet BioTherapeutics (SONN)|MAIA: Net earnings per share change forecast for next year|Liminatus Pharma Corp - Expected earnings per share growth for next year|LAVA Therapeutics NV (LVTX) - Expected net earnings per share growth next year|NXTC: Expected earnings per share growth for next year|Leap Therapeutics, Inc. (LPTX) - Expected earnings per share growth for next year|INTS: Earnings growth forecast for next year|Expected net earnings per share growth next year Sensei Biotherapeutics, Inc. (SNSE)|Net earnings per share growth forecast for next year Synthetic Biologics|GRTS: Expected earnings per share trend next year|Earnings growth forecast for next year KA|NEXI - Expected net earnings per share growth next year|Turnstone Biologics Corp. - Expected earnings per share growth for next year|VCNX - Expected earnings per share growth for next year|HARP - Net earnings per share growth forecast for next year
